BIOATLA, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
BIOATLA, INC. (BCAB) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $3.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-13
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $53.00K, a 45.92% decline year-over-year.
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $98.00K, a 34.23% decline year-over-year.
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $100.00K, a 70.76% decline from fiscal 2024.
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $342.00K, a 1.79% increase from fiscal 2023.
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $336.00K, a 16.26% increase from fiscal 2022.
- BIOATLA, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $289.00K, a 0.00% change from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $53.00K derived: sum of 2 quarters · filed 2026-03-31 | $100.00K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $47.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $47.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $98.00K derived: sum of 2 quarters · filed 2026-03-31 | $342.00K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $244.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $244.00K 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $163.00K derived: sum of 2 quarters · filed 2025-03-28 | $336.00K 10-K · filed 2025-03-28 | |
| 2023-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $187.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $173.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $270.00K derived: sum of 2 quarters · filed 2024-03-26 | $289.00K 10-K · filed 2024-03-26 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $19.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $19.00K 10-Q · filed 2023-08-01 | |||
| 2021-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $99.00K derived: sum of 2 quarters · filed 2023-03-23 | $289.00K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $190.00K 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $190.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |